Spyre Therapeutics
Develops extended-half-life antibody combinations for bowel, rheumatic, and dermatologic diseases.
$90.05
After-hours close−0.31 (−0.34%)
At close$90.36(−3.48%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 117.63%Insiders 0.86%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 86.84M · Float 77.45M · 89.2% free float
Institutions13F, as of Jun 30, 2026
274 holders · 102.15M shares · 93 new positions · 196 increased · 56 reduced · 24 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 13.03M | 15.00% | +1.25M | Aug 13, 2026 |
| BlackRock, Inc. | 6.51M | 7.49% | +985.4K | Aug 7, 2026 |
| Perceptive Advisors LLC | 4.32M | 4.97% | +536.3K | Aug 14, 2026 |
| RTW Investments, LP | 4.25M | 4.90% | +80.0K | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 3.84M | 4.42% | +1.88M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.45M | 3.97% | +391.3K | Aug 13, 2026 |
| State Street Corp | 3.06M | 3.52% | +450.4K | Aug 7, 2026 |
| VR Adviser, LLC | 2.99M | 3.44% | −700.0K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Tomas Kiselakincl. Fairmount Healthcare Fund II L.P., Peter Evan Harwin +1 more | 9.99% | 9.67M | 13D | Jun 23, 2026 ↗ |
| Peter E. Deutsch | 6.99% | 3.55M | 13G | Oct 23, 2024 ↗ |
| BlackRock, Inc. | 6.60% | 3.96M | 13G | Jul 16, 2025 ↗ |
| RTW Investments, LP | 6.20% | 3.62M | 13G | Feb 14, 2025 ↗ |
| Perceptive Advisors LLC | 5.00% | 4.32M | 13G | Apr 22, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Cameron Turtle | director, officer: Chief Executive Officer | 567.5K | 0.65% | Aug 5, 2026 |
| Scott L. Burrows | officer: Chief Financial Officer | 98.0K | 0.11% | Aug 5, 2026 |
| Michael Thomas Henderson | director | 68.6K | 0.08% | Jun 23, 2026 |
| Jeffrey W. Albers | director | 9.4K | 0.01% | Aug 10, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 7, 2026 | Jeffrey W. Albersdirector | Sale · 3 lots | 23,000 | $104.53 | 9,360 |
| Aug 3, 2026 | Cameron Turtledirector, officer: Chief Executive Officer | Sale · 5 lots | 15,000 | $95.51 | 567,540 |
| Aug 3, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale · 3 lots | 7,500 | $95.57 | 97,994 |
| Jul 1, 2026 | Cameron Turtledirector, officer: Chief Executive Officer | Sale · 3 lots | 15,000 | $87.69 | 582,540 |
| Jul 1, 2026 | Sheldon Sloanofficer: Chief Medical Officer | Sale · 2 lots | 8,334 | $87.70 | 0 |
| Jul 1, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale · 2 lots | 7,500 | $87.74 | 97,994 |
| Jun 25, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale · 2 lots | 15,000 | $87.13 | 97,994 |
| Jun 22, 2026 | Michael Thomas Hendersondirector | Sale | 20,000 | $100.00 | 68,606 |
| Jun 23, 2026 | Fairmount Funds Management LLCdirector | Sale | 4,684,781 | $85.31 | 0 |
| Jun 1, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale · 3 lots | 7,500 | $71.06 | 97,994 |
CongressHouse and Senate disclosures
Not reported.